Skip to main content

LIVE

OverviewAnalystsInstitutionalElite HoldersEarningsNews
MNPR

Monopar Therapeutics Inc.

MNPR

NASDAQ·Healthcare·Biotechnology·Mkt cap $787.5M

$117.56

▼ -0.84%

P/E

-50.24

Mkt Cap

$787.5M

52-Wk Range

$41.12–$124.82

52-Week Range

$41.12 - $124.82

P/E

-50.24

Fwd P/E

-40.59

Beta

1.50

Div Yield

0.00%

Avg Vol

206.2K

Shares Out

6.7M

Mkt Cap

$787.5M

Price action

Price chart

Up 183.4% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

3 reasons

  • Lead candidate Validive addresses significant unmet need in chemoradiotherapy side effects with clear clinical pathway
  • Novel doxorubicin analogs (Camsirubicin, MNPR-202) targeting resistant cancers with differentiated mechanisms
  • Strategic partnerships with established research institutions validating scientific approach and expanding development reach
▼

Bear Case

1 risk

  • Average volatility.

Growth

Stable outlook

Validive Phase 2b/3 clinical trial progression and potential regulatory approval pathway

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+94.0% over 3m

Quality

Loss-making

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 6, 2026

“
Q3 26 RECAP

AUG 12, 2026

Reported EPS of -$0.62 vs -$0.64 consensus (+3.5% surprise).

EPS beat +3.5%

EPS surprise · last 4Q

1 of 1 beats

Estimate

Actual

Q3 26

+3.5%

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

5 analysts · 80% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

4

80%

Hold

1

20%

Sell

0%

Median Price Target

$105.00

▼ -10.7% vs $117.56

Low $105.00
Median $105.00
High $105.00

Latest: Barclays · Aug 13, 2026

1 analyst covering

View full analyst page →

vs Industry

How MNPR stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.